Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study.
| Title: | Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study. |
|---|---|
| Authors: | Krishnan A; Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC, USA.; Department of Medicine, Section of Hematology and Oncology, Wake Forest University School of Medicine, Winston Salem, NC, USA.; Schneider CV; Department of Internal Medicine III, RWTH Aachen University, Aachen, Germany.; Arkenau HT; Sarah Cannon Research Institute, Cancer Institute, University College London, London, UK.; Mauro EM; Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Forner A; Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.; Scott Butsch W; Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, OH, USA.; Walsh D; Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC, USA.; Alqahtani SA; Organ Transplant Center of Excellence, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.; Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA. |
| Source: | Journal of clinical & translational endocrinology [J Clin Transl Endocrinol] 2024 Sep 18; Vol. 38, pp. 100370. Date of Electronic Publication: 2024 Sep 18 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: Netherlands NLM ID: 101629335 Publication Model: eCollection Cited Medium: Internet ISSN: 2214-6237 (Electronic) Linking ISSN: 22146237 NLM ISO Abbreviation: J Clin Transl Endocrinol Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [Amsterdam] : Elsevier Inc. |
| Abstract: | Aim: To examine the association between the use of incretin-based drugs [glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4Is)] and the risk of cholangiocarcinoma (CCA) in the United States.; Methods: This large population-based, retrospective cohort study using the TriNetX datasets included adult patients with type 2 diabetes mellitus (T2DM) who were new users of GLP-1RAs, DPP-4Is, or other second- or third-line antidiabetic drugs between 2010 and 2021. The primary outcome was the incidence of CCA.; Results: A total of 3,816,071 patients were included (mean age, 61.4 years, female, 49.3 %). A 51 % and 23 % risk reduction in CCA after 1 year of exposure to GLP-1RAs (hazard ratio 0.49; 95 % CI 0.40-0.60) and DPP4Is (0.77, 95 % CI 0.67-0.90), respectively compared to new second-or third-line users. Results were consistent at 3, 5, and 7 years of follow-up (0.66, 0.71, and 0.72 for GLP-1RAs and 0.84, 0.87, and 0.85 for DPP-4Is, respectively). Compared to new metformin users, GLP-1RA users were associated with a 42 % lower risk of developing CCA, whereas DPP-4I group was not associated with an increased risk.; Conclusions: GLP-1RAs and DPP-4Is were not associated with a significantly increased risk of CCA. GLP-1RAs even showed a reduced risk of CCA development. They can be considered as safe and effective treatment options for patients with T2DM at risk of CCA.; (© 2024 The Author(s).) |
| Competing Interests: | The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| References: | Hepatology. 2013 Feb;57(2):648-55. (PMID: 23055147); Mol Metab. 2021 Apr;46:101102. (PMID: 33068776); Diabetes Obes Metab. 2016 Feb;18(2):186-90. (PMID: 26443993); Sci Rep. 2021 Jan 28;11(1):2557. (PMID: 33510179); Diabetes Obes Metab. 2016 Mar;18(3):203-16. (PMID: 26489970); Am J Physiol Gastrointest Liver Physiol. 2012 Jan 15;302(2):G225-35. (PMID: 22038829); Sci Rep. 2017 Aug 15;7(1):8273. (PMID: 28811622); Endocr Relat Cancer. 2013 Jan 07;20(1):R1-R17. (PMID: 23207292); Acta Pharm Sin B. 2022 Nov;12(11):4040-4055. (PMID: 36386481); JAMA. 2021 Feb 16;325(7):686-687. (PMID: 33591334); Diabetologia. 2021 Oct;64(10):2204-2214. (PMID: 34254177); J Intern Med. 1991 Feb;229(2):181-7. (PMID: 1900072); Cureus. 2019 Jan 25;11(1):e3962. (PMID: 30956914); Endocr Pract. 2020 Jan;26(1):107-139. (PMID: 32022600); Discov Oncol. 2022 Aug 7;13(1):70. (PMID: 35933633); JAMA Intern Med. 2016 Oct 01;176(10):1474-1481. (PMID: 27478902); Cell Mol Life Sci. 2022 Apr 16;79(5):243. (PMID: 35429253); JAMA Health Forum. 2021 Dec 17;2(12):e214182. (PMID: 35977298); Front Oncol. 2020 Oct 27;10:587666. (PMID: 33194743); Acta Diabetol. 2020 Apr;57(4):401-408. (PMID: 31691043); Endocr Metab Immune Disord Drug Targets. 2015;15(3):196-205. (PMID: 25772174); Biomed Pharmacother. 2021 Aug;140:111778. (PMID: 34062416); Int J Obes (Lond). 2024 Feb 9;:. (PMID: 38336863); BMC Med Res Methodol. 2019 Mar 11;19(1):53. (PMID: 30871502); J Mol Endocrinol. 2013 Dec 19;52(1):R51-66. (PMID: 24049067); Diabetes Care. 2018 Aug;41(8):1663-1671. (PMID: 29898902); Can J Diabetes. 2021 Apr;45(3):282-290. (PMID: 33218924); Cancer Res. 2008 Aug 15;68(16):6752-61. (PMID: 18701500); Pharmacol Res. 2022 Aug;182:106320. (PMID: 35738455); Diabetes Care. 2020 Feb;43(2):487-493. (PMID: 31857443); Cancer Sci. 2020 Jun;111(6):1969-1978. (PMID: 32302443); Gastroenterology. 2007 Jul;133(1):244-55. (PMID: 17631146); Ann Oncol. 2016 Dec;27(12):2184-2195. (PMID: 27681864); J Hepatol. 2020 Jan;72(1):95-103. (PMID: 31536748); Basic Clin Pharmacol Toxicol. 2018 May;122(5):451-459. (PMID: 29265740); Pharmacoepidemiol Drug Saf. 2020 Sep;29(9):1101-1110. (PMID: 32783283); J Grad Med Educ. 2012 Sep;4(3):279-82. (PMID: 23997866); Nat Rev Endocrinol. 2009 May;5(5):262-9. (PMID: 19444259); Int J Biol Sci. 2021 May 11;17(8):2050-2068. (PMID: 34131405); Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. (PMID: 33298420); Diabetol Metab Syndr. 2022 Oct 21;14(1):153. (PMID: 36271423); Am J Med. 2009 Jun;122(6 Suppl):S3-S10. (PMID: 19464426); BMJ. 2018 Dec 5;363:k4880. (PMID: 30518618) |
| Contributed Indexing: | Keywords: Cholangiocarcinoma; Dipeptidyl peptidase 4 inhibitors; Glucagon-like peptide-1 receptor agonists; Incretin; Type 2 diabetes mellitus |
| Entry Date(s): | Date Created: 20241010 Latest Revision: 20241011 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11460491 |
| DOI: | 10.1016/j.jcte.2024.100370 |
| PMID: | 39386155 |
| Database: | MEDLINE |
Journal Article